Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $184.55, for a total transaction of $272,026.70. Following the sale, the vice president now owns 20,250 shares of the company’s stock, valued at $3,737,137.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of NYSE:EW traded down $0.71 during trading on Friday, hitting $183.93. 1,077,899 shares of the stock traded hands, compared to its average volume of 1,269,875. The company has a debt-to-equity ratio of 0.19, a current ratio of 3.66 and a quick ratio of 2.69. The firm has a market cap of $38.53 billion, a price-to-earnings ratio of 39.13, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. Edwards Lifesciences Corp has a 52-week low of $134.53 and a 52-week high of $197.86.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.09. The firm had revenue of $993.00 million during the quarter, compared to analyst estimates of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.22 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 5.29 earnings per share for the current fiscal year.

Several brokerages have commented on EW. Zacks Investment Research cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Credit Suisse Group lifted their price objective on shares of Edwards Lifesciences from $189.00 to $221.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Raymond James decreased their price objective on shares of Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating for the company in a research note on Wednesday, April 24th. Finally, BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a research note on Wednesday, April 24th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $186.52.

Several large investors have recently bought and sold shares of EW. Oregon Public Employees Retirement Fund increased its holdings in Edwards Lifesciences by 21,360.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock worth $69,000 after acquiring an additional 10,587,326 shares in the last quarter. Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter worth $559,646,000. Jennison Associates LLC increased its holdings in Edwards Lifesciences by 184.7% in the 4th quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock worth $629,855,000 after acquiring an additional 2,667,749 shares in the last quarter. FMR LLC increased its holdings in Edwards Lifesciences by 28.9% in the 4th quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock worth $1,160,540,000 after acquiring an additional 1,700,199 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Edwards Lifesciences by 7.4% in the 4th quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock worth $2,516,802,000 after acquiring an additional 1,128,082 shares in the last quarter. 82.12% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Edwards Lifesciences Corp (NYSE:EW) VP Sells $272,026.70 in Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/edwards-lifesciences-corp-nyseew-vp-sells-272026-70-in-stock/3041869.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: How is the Producer Price Index calculated?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.